Abstract:Objective: To investigate mechanism of cyclooxygenase-2 (COX-2) in bone loss in a postmenopausal osteoporosis (PMOP) rat mode with ovarietomy (OVX). Methods: Forty female Sprague Dawley adult rats at age of 3 months were randomly divided into 4 groups, 10 in each group, including sham-operated (sham) group, OVX group, OVX treated with nilesteriol (OVX + E) group and OVX treated with aspirin (OVX + P) group. All rats in OVX, OVX + E and OVX + P groups underwent ovarietomy under abdominal anesthesia with 10% chloral hydrate. Rats in sham group were only taken with fat tissue with same weight under bilateral ovary. After surgery, penicillin was administered to prevent infection. At day 7 after surgery, agents were given by intragastric administration for 12 weeks. Nilestriol at 1.0 mg/kg was used in OVX + E group once a week, aspirin at 45 mg×kg⁻¹(×d⁻¹ was used in OVX + P group once a day. Saline with same volume was used in rats in sham and OVX groups. All agents were administered one time per day. Dose of agents were adjusted by weight per week. At end of study, bone mineral density (BMD) of right femurs and lumbar vertebrae 3-5 (L(3-5)) were measured. Morphology of bone was detected by hematoxylineosin, and expression of COX-2 was determined by immunohistochemistry staining. Results: (1) BMD:BMD of right femur and L(3-5) was (0.209 ± 0.010) g/cm² and (0.230 ± 0.012) g/cm² in sham group and (0.181 ± 0.008) g/cm² and (0.201 ± 0.016) g/cm² in OVX group, which reached statistical difference (P < 0.01). BMD of right femur and L(3-5) was (0.203 ± 0.009) g/cm² and (0.224 ± 0.028) g/cm² in OVX + E group and (0.200 ± 0.011) g/cm² and (0.204 ± 0.003) g/cm² in OVX + P group, which were all higher than those in OVX group (P < 0.01, P < 0.05). However, there was no statistical difference in BMD between OVX + E and OVX + P group (P > 0.05). (2) Morphology of bone:bone trabeculae became fewer and degenerated in OVX group. However, bone trabeculae were regular and dense in OVX + P group and OVX + E group, which were similar to those in sham group. (3) Expression of COX-2:cells with COX-2 positive and expression of COX-2 around bone trabeculae in OVX group were more than those in sham, OVX + E and OVX + P group. Conclusion: COX-2 plays an important role in PMOP. Aspirin could prevent bone loss by decreasing COX-2 expression in OVX rats.

Study of effect and mechanism of cyclooxygenase-2 on the prostatic hyperplasia in rats

Effect of nitric oxide on the prostatic proliferation/apoptosis in rats

Protective effect of bamboo shoot oil on experimental nonbacterial prostatitis in rats

The effect of COX-2 inhibitor on bladder cancer

Effect of Endothelin-1 on Cyclooxygenase-2 Expression in Human Hormone Refractory Prostate Cancer Cells

COX-1 and -2 expressions in sex-related organs of neonatally estrogen-treated rats and in activated and nonactivated macrophage RAW264.7 cells with phytoestrogen

Prostaglandin E2 Mediates Up-regulation of ERRα Expression with BPH-1 Condition Medium in Prostatic Stromal Cells

Sex hormone-binding globulin mediated cAMP activation in cultured prostate cells caused by estradiol

The Therapeutic Effects of Docosahexaenoic Acid on Oestrogen/androgen-Induced Benign Prostatic Hyperplasia in Rats

The prostaglandin synthases, COX-2 and L-PGDS, mediate prostate hyperplasia induced by low-dose bisphenol A

Chemopreventive effect of cyclooxygenase-2 specific inhibitor on chemically induced breast cancer in rats

Study on the alteration of nNOS, eNOS expression in corpus cavernosum of prostate hyperplasia model in rats

Inhibitive effect of COX-2 on human bladder cancer cell xenografts in nude mice

Study on the Effect of Heme Oxygenase-1 on Prostate Cancer

Cyclooxygenase-2 activates EGFR–ERK1/2 pathway via PGE2-mediated ADAM-17 signaling in testosterone-induced benign prostatic hyperplasia

Individual and Combined Effect of Bisphenol A and Bisphenol AF on Prostate Cell Proliferation Through NF-κB Signaling Pathway

[Effect of cyclooxygenase-2 on bone loss in ovariectomized rats]

Effect of Rofacoxib, a highly selective cyclooxygenase-2 inhibitor, on portal pressure in cirrhotic rats

Cryptotanshinone modulates proliferation, apoptosis, and fibrosis through inhibiting AR and EGFR/STAT3 axis to ameliorate benign prostatic hyperplasia progression

[Expression and Implication of Cyclooxygenase-2 Mrna in Prostate Cancer].

S100A4 modulates cell proliferation, apoptosis and fibrosis in the hyperplastic prostate